Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.
A 2008 review by our group concluded that the risk of neuropsychiatric adverse events (NPAEs) in influenza patients was not increased by oseltamivir exposure, and did not identify any mechanism by which oseltamivir or its metabolites could cause or worsen such events. The current article reviews new information on this topic. Between September 16, 2007 and May 15, 2010, 1,805 spontaneously-reported NPAEs were identified in 1,330 patients receiving oseltamivir: 767 (42.5%) from Japan, 296 (16.4%) from the USA, and 742 (41.1%) from other countries. NPAEs were more common in children: 1,072 (59.4%) events were in those aged ≤16 years. NPAEs often occurred within 48 h of treatment initiation (953 events; 52.8%). Nearly half of the events were serious in nature (838; 46.4%). The three largest categories of events were abnormal behavior (457 events, 25.3%), miscellaneous psychiatric events (370; 20.5%), and delusions/perceptual disturbances (316 events, 17.5%). A total of 1,545 events (85.6%) in eight different categories were considered to be delirium or delirium-like. Twenty-eight suicide-related events were reported. A US healthcare claims database analysis showed that the risk of NPAEs in 7,798 oseltamivir-treated patients was no higher than that in 10,411 patients not on antivirals, but a study on oseltamivir and abnormal behavior in Japan was less conclusive. NPAE frequency in oseltamivir-exposed Japanese and Taiwanese children with influenza was the same as in unexposed children. New analysis of the UK General Practice Research Database showed that the relative adjusted risk of NPAEs in influenza patients was 2.18-times higher than in the general population. Other epidemiology studies report frequent occurrence of encephalitis and similar disorders in influenza patients independently of oseltamivir exposure. The new data support the findings of the original assessment. Evidence suggests that influenza-related encephalopathies are caused by influenza-induced inflammatory responses, but more work is needed to confirm the underlying mechanisms.
F. Hoffmann-La Roche Ltd., PBMT Bldg. 74/3O Z01.05, CH-4070, Basel, Switzerland. malaria@sunrise.ch
Stephen
S
Toovey
Eric P
EP
Prinssen
Craig R
CR
Rayner
Bharat T
BT
Thakrar
Regina
R
Dutkowski
Annette
A
Koerner
Tom
T
Chu
Alexandra
A
Sirzen-Zelenskaya
Markus
M
Britschgi
Sudhir
S
Bansod
Barbara
B
Donner
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D002648:Child; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D001523:Mental Disorders / Q000139:chemically induced*; D053139:Oseltamivir / Q000009:adverse effects*
D000998:Antiviral Agents; D053139:Oseltamivir